Insufficient Control of E-cigarette Sales to Minors in Russia

Regulations by 2FIRSTS.ai
Feb.26.2024
Insufficient Control of E-cigarette Sales to Minors in Russia
Russian public chamber member and internet security alliance director Ekaterina Mizulina calls for better control on e-cigarette sales for minors.

According to a report by TASS on February 24th, Ekaterina Mizulina, a member of the Russian Public Chamber and Director of the Safe Internet Alliance, expressed concern during a meeting with students about the inadequate control over the sale of e-cigarettes to minors. She called for organized action to be taken, involving consumer rights protection organizations, public health supervision agencies, and volunteers.

 

Mizulina emphasized during a meeting with students in Tyumen that the current monitoring of e-cigarette sales is insufficient and called for systematic action to be taken through the involvement of consumer rights protection and public health oversight agencies, as well as volunteers.

 

She reminded the public that a law restricting the sale of e-cigarettes to minors has been in effect since June 1st of last year. Mizulina believes that this mechanism has not been fully effective, as children are still able to purchase these products on the streets and online.

 

She emphasized, "This indicates that the current monitoring is insufficient, so we need systematic action from consumer rights protection and public health supervision agencies, as well as volunteers, to stop this behavior." Previously, Marlin Gambaryan, Director of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, had advocated for a complete ban on the sale of e-liquid substances.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

InterTabac 2025 Insights|BAT Exhibits Full Portfolio, Highlights VUSE Ultra and Introduces Zero-Nicotine Products
InterTabac 2025 Insights|BAT Exhibits Full Portfolio, Highlights VUSE Ultra and Introduces Zero-Nicotine Products
2Firsts’ on-site reporting at InterTabac 2025 in Dortmund, Germany, found that BAT showcased a range of HTP, e-vapor, and nicotine pouch products, with a focus on zero-nicotine e-vapor and the VUSE Ultra line, and set up an interactive experience area.
Sep.19 by 2FIRSTS.ai
Product | GEEKBAR Launches First DTL Model in the U.S. with 5% Nicotine
Product | GEEKBAR Launches First DTL Model in the U.S. with 5% Nicotine
E-cigarette brand Geek Bar has recently introduced its first disposable vape with direct-to-lung (DTL) functionality to the U.S. market via distributor websites—the GEEKBAR Pulse X DTL 25K and GEEKBAR Pulse X DTL 42K. Both new models feature MTL/DTL mode switching and are differentiated by capacity, nicotine strength, and price positioning.
Aug.15 by 2FIRSTS.ai
Australia’s New Vape Laws Face International Trade Challenges
Australia’s New Vape Laws Face International Trade Challenges
Australia has enacted the world’s toughest e-cigarette regulations to combat the youth vaping epidemic, but new research warns that these measures may face challenges under international trade rules. Experts caution that without sufficient scientific evidence and a global perspective, Australia’s laws could face complaints at the World Trade Organization (WTO) and potentially be dismantled. Researchers urge Australia to draw lessons from its tobacco plain packaging case, preparing strong evidenc
Aug.21 by 2FIRSTS.ai
2Firsts Analysis: 69.8% of North American Cannabis Vapes Lack Clear Ingredient Labeling, Raising Compliance and Safety Concerns
2Firsts Analysis: 69.8% of North American Cannabis Vapes Lack Clear Ingredient Labeling, Raising Compliance and Safety Concerns
In August 2025, the Journal of Studies on Alcohol and Drugs published a study analyzing the packaging of Delta-8 THC products in North America. 2Firsts focused on the cannabis vape segment, which accounts for 37.9% of the sample, often with high concentrations—yet 69.8% lacked clear potency information, and only 11.7% carried health warnings on the main display panel.
Aug.15 by 2FIRSTS.ai
Imperial Brands Launches £1.45B Buyback Plan as New Product Revenue Jumps 12-14%
Imperial Brands Launches £1.45B Buyback Plan as New Product Revenue Jumps 12-14%
Imperial Brands: FY results in line; launches £1.45bn buyback (to Oct 2026). Constant-currency net revenue to grow low single digits; NGP +12%–14%; adjusted operating profit growth similar to last year’s 4.6%.
Oct.07 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai